NCT07287852Enrolling by invitationPhase 2
A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the drug Egb761, produced from Ginkgo Biloba extract, works to improve the blood level of a biomarker of Alzheimer's disease, called phosphorylated-tau217 (p-tau217), which serves as a biomarker for disease activity in the brain. The main questions it aims to answer are: Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity? Participants will: Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 29 Jun 2025
- Start date
- 20 Aug 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Hadassah Medical Organization
- Diseases
- Alzheimer disease
- NCT number
- NCT07287852
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 20 Aug 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Extrapyramidal signs, existence of multi-infract dementia, or Fronto-Temporal dementia, according to clinical impression by treating cognitive Neurologist.
- Active cancer, severe cardio-pulmonary disease or other medical condition which negatively affects ability to evaluate patients and complete follow-up.
- Inability to sign an informed consent due to psychiatric or dementing condition.
- Hypersensitivity to any ingredient of the study medication.
Who the study is looking for
- Mild cognitive impairment, as defined by MoCA score of 19-25.
- Preserved instrumental activities of daily life (iADL).
- Clinical impression of MCI of AD type, and lack of major medical and neurological conditions, as detailed in the exclusion criteria.
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hadassah medical Center Coordinator of this site? Confirm its status | Jerusalem | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.